[Immunity to measles after vaccination of children with rheumatic diseases].
Medical history, immunization status were studied and serologic tests were performed in 72 children aged 1-16 years (mean age 10.8 +/- 0.49 years) with rheumatic diseases (juvenile rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Overlap-syndrome, etc.). Three hundred people aged 3-26 years belonging to indicator groups were included in the control group. Real protection was achieved in 77.8% of patients with rheumatic diseases. Sixteen patients (22.2%) did not have protective antibody titers, of which 5 were not vaccinated. From children with rheumatic diseases received 1 dose of vaccine 14.8% (4 out of 27) were seronegative, whereas from those received 2 doses 22.5% (9 out of 40) were seronegative. Difference in mean optical density (OD) of serum samples obtained in children from control group, which received 1 or 2 doses of vaccine, was not observed (delta 1.02 +/- 0.16 and delta 0.74 +/- 0.09 respectively). Decline of antibody titers with time after vaccination in children with rheumatic diseases immunized with 2 doses of vaccine was observed (r= -0.42, P=0.008).
Tarasova
A A
AA
Kostinov
M P
MP
Korovkina
T I
TI
D000293:Adolescent; D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008457:Measles / Q000150:complications / Q000276:immunology* / Q000517:prevention & control*; D008458:Measles Vaccine / Q000008:administration & dosage* / Q000276:immunology; D012216:Rheumatic Diseases / Q000150:complications / Q000276:immunology*; D012426:Russia / Q000453:epidemiology; D014611:Vaccination
D000914:Antibodies, Viral; D008458:Measles Vaccine